BR112022006739A2 - Conjugados fosfolipídio-flavagina e métodos de uso do mesmo para terapia direcionada a câncer - Google Patents

Conjugados fosfolipídio-flavagina e métodos de uso do mesmo para terapia direcionada a câncer

Info

Publication number
BR112022006739A2
BR112022006739A2 BR112022006739A BR112022006739A BR112022006739A2 BR 112022006739 A2 BR112022006739 A2 BR 112022006739A2 BR 112022006739 A BR112022006739 A BR 112022006739A BR 112022006739 A BR112022006739 A BR 112022006739A BR 112022006739 A2 BR112022006739 A2 BR 112022006739A2
Authority
BR
Brazil
Prior art keywords
phospholipid
methods
conjugates
cancer
flavagin
Prior art date
Application number
BR112022006739A
Other languages
English (en)
Other versions
BR112022006739B1 (pt
Inventor
Longcor Jarrod
Original Assignee
Cellectar Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellectar Biosciences Inc filed Critical Cellectar Biosciences Inc
Publication of BR112022006739A2 publication Critical patent/BR112022006739A2/pt
Publication of BR112022006739B1 publication Critical patent/BR112022006739B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

CONJUGADOS FOSFOLIPÍDIO-FLAVAGINA E MÉTODOS DE USO DO MESMO PARA TERAPIA DIRECIONADA A CÂNCER. São divulgadas neste documento moléculas de éter fosfolipídico (PLE). Além disso, são fornecidos conjugados de fosfolipídio-flavaglina. O conjugado fosfolipídio- flavaglina pode incluir um PLE conjugado com uma flavaglina por meio de um ligante. Além disso, são fornecidos neste documento métodos de tratamento de câncer em um sujeito e métodos de direcionamento de um fármaco para um tumor ou célula cancerosa em um sujeito.
BR112022006739-9A 2019-10-10 2020-10-09 Conjugados fosfolipídio-flavagina e métodos de uso do mesmo para terapia direcionada a câncer BR112022006739B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962913571P 2019-10-10 2019-10-10
US62/913,571 2019-10-10
PCT/US2020/055121 WO2021072300A1 (en) 2019-10-10 2020-10-09 Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy

Publications (2)

Publication Number Publication Date
BR112022006739A2 true BR112022006739A2 (pt) 2022-06-28
BR112022006739B1 BR112022006739B1 (pt) 2024-01-23

Family

ID=75436788

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022006739-9A BR112022006739B1 (pt) 2019-10-10 2020-10-09 Conjugados fosfolipídio-flavagina e métodos de uso do mesmo para terapia direcionada a câncer

Country Status (10)

Country Link
EP (1) EP4041718A4 (pt)
JP (1) JP2022551495A (pt)
KR (1) KR20220080139A (pt)
CN (1) CN114761389A (pt)
AU (1) AU2020361679A1 (pt)
BR (1) BR112022006739B1 (pt)
CA (1) CA3154192A1 (pt)
IL (1) IL291979A (pt)
MX (1) MX2022004341A (pt)
WO (1) WO2021072300A1 (pt)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007528374A (ja) * 2004-03-02 2007-10-11 セレクター，リミティド ライアビリティ カンパニー Ｄｉａｐｅｕｔｉｃ（登録商標）剤としてのリン脂質類似体、及びその方法
WO2010056919A2 (en) * 2008-11-12 2010-05-20 Kyphia Pharmaceuticals, Inc. Eflornithine prodrugs, conjugates and salts, and methods of use thereof
SI3708192T1 (sl) * 2009-06-12 2023-12-29 Cellectar, Inc. Eter fosfolipidne spojine za zdravljenje raka in slikanje in detekcijo rakavih izvornih celic
US20140255432A1 (en) * 2011-07-27 2014-09-11 Ohio State Innovation Foundation Silvestrol, silvestrol analogs and uses thereof
WO2014106826A2 (en) * 2013-01-07 2014-07-10 Piramal Enterprises Limited Anthracycline analogue and uses thereof
FR3023290B1 (fr) * 2014-07-04 2016-08-19 Pf Medicament Derives de flavaglines
US9925269B2 (en) * 2014-11-17 2018-03-27 Cellectar Biosciences, Inc. Phospholipid ether analogs as cancer-targeting drug vehicles
WO2017214024A1 (en) * 2016-06-06 2017-12-14 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use

Also Published As

Publication number Publication date
IL291979A (en) 2022-06-01
EP4041718A1 (en) 2022-08-17
CN114761389A (zh) 2022-07-15
JP2022551495A (ja) 2022-12-09
BR112022006739B1 (pt) 2024-01-23
CA3154192A1 (en) 2021-04-15
EP4041718A4 (en) 2023-12-20
WO2021072300A1 (en) 2021-04-15
KR20220080139A (ko) 2022-06-14
AU2020361679A1 (en) 2022-04-28
MX2022004341A (es) 2022-08-10

Similar Documents

Publication Publication Date Title
JOP20210074A1 (ar) مترافقات جسم مضاد وعقار أساسها إيريبولين وطرق استخدامها
BR112012026213A2 (pt) pirrolobenzodiazepinas e conjugados das mesmas
CY1122855T1 (el) Θεραπευτικα συστατικα δεσμευσης κυτταρικης επιφανειας με αματοξινη για τη θεραπεια ογκου
NZ739780A (en) Compositions, combinations and related methods for photoimmunotherapy
MX2019008059A (es) Anticuerpo anti-gpr20 y conjugado de anticuerpo-medicamento anti-gpr20.
BR112019008854A2 (pt) ligantes contendo peptídeo para conjugados de anticorpo-fármaco
MX2017003246A (es) Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer.
CL2021000901A1 (es) Enlazadores de conjugación que contienen el grupo 2,3-diaminosuccinilo
NZ741261A (en) Pyrrolobenzodiazepine antibody drug conjugates and methods of use
ECSP19044625A (es) Conjugados anticuerpo-droga para ablación de células madre hematopoyéticas
EA033456B1 (ru) Конъюгаты антитело-лекарственное средство, содержащие пептидомиметические линкеры
AR069903A1 (es) Conjugado anticuerpo- molecula asociada dirigidos a la proteina tirosina quinasa 7 (ptk 7), composicion farmaceutica que lo comprende, acido nucleico, factor de expresion y celula huesped relacionados y su uso para preparar un medicamento util para el tratamiento o prevencion de cancer
AR096015A1 (es) Conjugados de fármacos con anticuerpos
BR112016005802A2 (pt) conjugados de clorotoxina e métodos de seu uso
BR112015023333A8 (pt) pirrolbenzodiazepinas e conjugados dos mesmos
BR112012031727A2 (pt) conjugado de droga-anticorpo, composição farmacêutica, uso do conjugado de droga-anticorpo, método para induzir a eliminação celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, método de tratamento de doença.
MX2020012679A (es) Compuestos de amino-pirazincarboxamida, conjugados, y usos de los mismos.
BR112016016202A2 (pt) Construtos de direcionamento de receptores e uso dos mesmos
AU2017250507A8 (en) Methods of treatment using chlorotoxin conjugates
CY1121667T1 (el) Παραγοντες για θεραπεια τριπλα αρνητικου καρκινου μαστου
AR104484A1 (es) Anticuerpos anti-psma como agentes terapéuticos
MX2019009726A (es) Moleculas con direccion hacia her2 que comprenden andamiajes de la sub-unidad a de la toxina shiga desinmunizados.
CO2023004252A2 (es) Anticuerpos anti-ceacam5 y conjugados y usos de los mismos
UY35250A (es) Anticuerpos anti-lamp1 y conjugados anticuerpo fármaco, y usos de éstos.
CY1126032T1 (el) Συζευγματα αντισωματος-φαρμακου που στοχευουν uparap

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/10/2020, OBSERVADAS AS CONDICOES LEGAIS